Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a clinical stage, publicly traded company listed on the Nasdaq stock exchange (ticker ARWR) headquartered in Pasadena, California. The company employs 70 people. Arrowhead Pharmaceuticals develops RNA interference (RNAi)-based therapeutics to treat intractable diseases by silencing the genes responsible for them. Their Targeted RNAi Molecule (TRiM) platform utilizes ligand-mediated delivery and is designed for tissue-specific targeting, offering simplified manufacturing, reduced costs, multiple administration routes, and potential for improved safety. Their therapies leverage RNA interference, a natural cellular mechanism that inhibits gene expression, thereby affecting protein production. Arrowhead's RNAi-based therapeutics hold the potential to revolutionize genetic-based therapy and provide life-changing treatments for patients. Further inquiries can be directed to Arrowhead Pharmaceuticals through their website at arrowheadpharma.com.